DNA immunotherapies for hepatitis
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections pose a significant global public-health problem and are major causes of chronic liver disease. Three to five times more people are living with chronic viral hepatitis infections than with HIV infection. In the U.S., it is estimated that as many as 5.3 million people—about 1 in every 50 people—are living with chronic HBV or HCV infections.
Current therapies are associated with significant side effects. Inovio believes a DNA immune therapy to treat HBV and/or HCV would offer physicians a powerful tool in the fight against this all-too common infectious disease. Inovio’s strategy is to advance hepatitis synthetic vaccines through multiple collaborations to fund and conduct relevant clinical studies, as shown in the table below.
|Candidate||Vaccine Type||Disease Type||Target Antigens||Collaborator|
|HBV||Synthetic multi-antigen DNA immunotherapy||Hepatitis B virus
clades A & C
|Surface & core||Roche|
|HCV||Synthetic multi-antigen DNA immunotherapy||Hepatitis C virus genotypes 1a and 1b||NS3/4A, NS4B, NS5A||GeneOne Life Sciences, Inc.|